Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Sedatives and Hypnotics: Overview01:23

Sedatives and Hypnotics: Overview

765
Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
765
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

269
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
269
Sedatives and Hypnotics Drugs: Benzodiazepines01:19

Sedatives and Hypnotics Drugs: Benzodiazepines

421
Benzodiazepines have both sedative and hypnotic properties. They include compounds such as diazepam (Valium) and alprazolam (Xanax). Structurally, their cores are similar, consisting of the fusion of a benzene ring and a diazepine ring, but they share a common mechanism of action in the central nervous system (CNS).
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
421
Sedatives and Hypnotics Drugs: Barbiturates01:20

Sedatives and Hypnotics Drugs: Barbiturates

566
Sedatives and hypnotics encompass a drug class that acts on the central nervous system (CNS) to alleviate anxiety, promote relaxation and induce sleep.These drugs function by amplifying the actions of the neurotransmitter γ-aminobutyric acid (GABA), resulting in reduced neuronal activity. Barbiturates, a subset of sedatives and hypnotics first synthesized in the late 1800s, are categorized into ultra-short, short, intermediate, and long-acting groups based on their duration of effect. A...
566
CNS Depressants: Barbiturates and Benzodiazepines01:14

CNS Depressants: Barbiturates and Benzodiazepines

648
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
648
Depressants01:28

Depressants

192
Depressant drugs, including alcohol and sedative-hypnotics, diminish central nervous system activity by enhancing the action of gamma-aminobutyric acid (GABA), a neurotransmitter that reduces brain activity and promotes relaxation. These substances can have various therapeutic uses but also pose significant risks, especially when misused or combined.
Alcohol is a common depressant that can induce a sense of relaxation and reduced inhibition at low doses. Contrary to its occasional...
192

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Case for Building Physician Engagement and Competencies in Quality & Safety… and How to Do It.

Quality management in health care·2026
Same author

Effect of electron beam irradiation of piroxicam on inhibiting the inflammatory response in LPS-stimulated BMDCs and sepsis-induced mouse models.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Towards use of Patient-informed Relevant Outcomes (PRO) in trials of bloodstream infections: a mixed-methods study protocol (BALANCE+PRO).

BMJ open·2026
Same author

Flexible Semitransparent MXene Thin-Film Heaters Enhanced by Conducting Polymer Percolation Network.

ACS applied materials & interfaces·2026
Same author

Supply Chain Events and Risk of Drug Shortage in Canada.

JAMA network open·2026
Same author

Survey of Intensivist Coverage and Interprofessional Team Staffing in Canadian ICUs.

Critical care medicine·2026

Related Experiment Video

Updated: Oct 8, 2025

Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea
07:54

Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea

Published on: December 6, 2016

20.0K

Reducing Sedative-Hypnotics Among Hospitalized Patients: a Multi-centered Study.

Christine Soong1,2,3, Cheryl Ethier4, Yuna Lee5

  • 1Divisions of General Internal Medicine and Hospital Medicine, Sinai Health System, Toronto, ON, Canada. christine.soong@utoronto.ca.

Journal of General Internal Medicine
|January 4, 2022
PubMed
Summary

A quality improvement bundle successfully reduced sedative-hypnotic prescriptions for hospitalized patients new to these drugs. This initiative decreased medication use without negatively impacting patient safety outcomes like falls or mortality.

More Related Videos

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
09:36

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

2.9K
Through-the-Wall Blood Sampling Method to Minimize Sleep Disruption in Clinical Settings
06:39

Through-the-Wall Blood Sampling Method to Minimize Sleep Disruption in Clinical Settings

Published on: June 13, 2025

153

Related Experiment Videos

Last Updated: Oct 8, 2025

Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea
07:54

Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea

Published on: December 6, 2016

20.0K
Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
09:36

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

2.9K
Through-the-Wall Blood Sampling Method to Minimize Sleep Disruption in Clinical Settings
06:39

Through-the-Wall Blood Sampling Method to Minimize Sleep Disruption in Clinical Settings

Published on: June 13, 2025

153

Area of Science:

  • Hospital Quality Improvement
  • Pharmacology
  • Patient Safety

Background:

  • Sedative-hypnotics are commonly prescribed for insomnia in hospitals.
  • Their use is linked to preventable patient harms.
  • Reducing their use in naive patients is a key safety goal.

Purpose of the Study:

  • To evaluate a quality improvement bundle designed to decrease sedative-hypnotic use.
  • To assess the bundle's impact on hospitalized patients previously naive to sedative-hypnotics.

Main Methods:

  • An interrupted time series study was conducted across 7 inpatient wards in 5 teaching hospitals.
  • The intervention involved a bundle of strategies including order set changes, audit-feedback, and education.
  • Data were collected for one year prior to the intervention and at least 16 months post-implementation.

Main Results:

  • The proportion of sedative-hypnotic-naïve inpatients newly prescribed a sedative-hypnotic significantly decreased from 15.48% to 9.08% (p<0.001).
  • No significant changes were observed in secondary outcomes, including mortality, falls, or prescriptions for other sedating medications.
  • The reduction in sedative-hypnotic prescriptions was sustained throughout the intervention period.

Conclusions:

  • A sedative-hypnotic reduction quality improvement bundle effectively and sustainably decreased sedative-hypnotic prescriptions in hospitalized patients.
  • The findings support the implementation of such bundles to improve medication safety.
  • This intervention offers a promising approach to mitigate risks associated with sedative-hypnotic use in hospitals.